NTIS in ICU

The Endocrinology of Critical Illness: The Non-Thyroidal Illness Syndrome (NTIS)

Dr Neeraj Manikath , claude.ai

Non-thyroidal illness syndrome (NTIS), also known as euthyroid sick syndrome, represents one of the most common endocrine abnormalities encountered in critically ill patients. This adaptive response to severe illness produces profound alterations in thyroid hormone metabolism that can mimic true thyroid disease, creating diagnostic and therapeutic challenges in the intensive care unit setting.

The "Sick Euthyroid" State: Low T3, High rT3, and Normal/High TSH

The hallmark of NTIS is a characteristic pattern of thyroid function test abnormalities that evolve with the severity and duration of illness. Despite these laboratory derangements, patients remain clinically euthyroid—their thyroid gland functions normally, and they lack true thyroid disease.

Early/Mild Illness Pattern: In the initial phases of acute illness, the most consistent finding is decreased serum triiodothyronine (T3), often falling to 50% or less of normal values within 24 hours of acute illness onset. This occurs alongside a reciprocal elevation in reverse T3 (rT3), the biologically inactive isomer of T3. Total and free thyroxine (T4) levels typically remain normal or slightly elevated initially, while thyroid-stimulating hormone (TSH) usually stays within the normal range, though it may be at the lower end.

Severe/Prolonged Illness Pattern: As illness severity progresses or critical illness becomes protracted, the biochemical picture evolves. T4 levels begin to decline—a particularly ominous prognostic sign, as low T4 in critical illness correlates with increased mortality. Free T4 may appear low, normal, or even paradoxically elevated depending on the assay method used (direct immunoassay versus equilibrium dialysis). TSH levels typically remain inappropriately normal or low given the low thyroid hormone levels, though transient TSH suppression may occur during the acute phase, sometimes falling below 0.1 mIU/L. In some cases, particularly with prolonged critical illness, TSH may actually be mildly elevated (up to 10-20 mIU/L), creating further diagnostic confusion.

The classic triad—low T3, high rT3, and normal or low-normal TSH—defines NTIS, though the complete picture varies with illness acuity and duration.

Pathophysiology: The Role of Deiodinases, Cytokines, and Altered Pituitary Feedback

The mechanisms underlying NTIS are complex and multifactorial, representing a coordinated response involving peripheral hormone metabolism, central regulation, and cellular thyroid hormone signaling.

Deiodinase Dysregulation: The deiodinase enzymes are central to NTIS pathophysiology. Type 1 deiodinase (D1), predominantly expressed in liver and kidney, normally converts T4 to the active hormone T3 and degrades rT3. In critical illness, D1 activity is markedly suppressed by inflammatory cytokines, reduced caloric intake, and elevated cortisol levels. This suppression simultaneously decreases T3 production from T4 and impairs rT3 clearance.

Type 3 deiodinase (D3), which inactivates T4 and T3 by converting them to rT3 and T2 respectively, becomes upregulated in multiple tissues during critical illness. This upregulation, driven by inflammatory signals and hypoxia-inducible factors, further accelerates the degradation of active thyroid hormones. Notably, D3 expression has been demonstrated in inflammatory cells and injured tissues, suggesting a localized protective mechanism.

Type 2 deiodinase (D2), which converts T4 to T3 in the brain and pituitary, may initially maintain local T3 concentrations despite low circulating levels, though this compensatory mechanism appears to fail in prolonged illness.

Inflammatory Cytokine Effects: Pro-inflammatory cytokines—particularly interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma—play pivotal roles in mediating NTIS. These cytokines directly inhibit thyroid hormone synthesis and release from the thyroid gland, suppress TSH secretion from the pituitary, downregulate deiodinase activity, reduce thyroid hormone binding protein synthesis, and impair cellular thyroid hormone receptor function and signaling.

The cytokine effects are dose-dependent, with the degree of thyroid function abnormality correlating with inflammatory marker levels and illness severity.

Altered Hypothalamic-Pituitary Axis: The hypothalamic-pituitary-thyroid axis undergoes fundamental changes during critical illness. Thyrotropin-releasing hormone (TRH) secretion from the hypothalamus decreases, while the normal pulsatile pattern of TSH secretion becomes disrupted. Despite low circulating thyroid hormone levels that would normally trigger robust TSH elevation, the TSH response remains blunted—an apparent "reset" of the feedback set point.

This altered feedback regulation appears to be mediated by several factors: maintained intrapituitary T3 levels through D2 activity (at least initially), direct cytokine suppression of thyrotroph function, elevated cortisol and dopamine effects on TSH secretion, and altered expression of thyroid hormone receptors in the pituitary.

Binding Protein and Transport Alterations: Critical illness reduces serum levels of thyroid hormone-binding proteins, particularly thyroxine-binding globulin (TBG) and transthyretin, through decreased hepatic synthesis and increased degradation. This reduction in binding capacity affects total hormone measurements more than free hormone levels. Additionally, accumulated inhibitors of thyroid hormone binding—including free fatty acids, bilirubin, and various medications—further alter the relationship between total and free hormone concentrations, complicating laboratory interpretation.

Cellular and Nuclear Effects: At the cellular level, critical illness impairs thyroid hormone entry into cells through downregulation of thyroid hormone transporters (particularly MCT8 and MCT10). Within cells, altered expression of thyroid hormone receptors and their coactivators/corepressors modifies thyroid hormone action, even when intracellular hormone availability is maintained.

Why Treating with Thyroid Hormone is Usually Not Indicated

Despite the dramatic alterations in thyroid function tests and the intuitive appeal of hormone replacement, multiple lines of evidence indicate that thyroid hormone treatment in NTIS is not beneficial and may be harmful.

NTIS as an Adaptive Response: The prevailing understanding views NTIS as a protective, adaptive mechanism rather than a pathological hormone deficiency requiring correction. The reduction in T3 and metabolic rate may serve several beneficial purposes: conservation of energy and protein stores during catabolic illness, reduction in oxygen consumption when tissue perfusion is compromised, limitation of free radical generation and oxidative stress, and protection against excessive catabolism and tissue breakdown.

This perspective is supported by evolutionary biology—similar responses occur across mammalian species during starvation, hibernation, and illness, suggesting fundamental survival value.

Clinical Trial Evidence: Multiple randomized controlled trials have evaluated thyroid hormone supplementation in various critical illness populations (cardiac surgery, burn injury, acute myocardial infarction, brain death organ donors, sepsis, and prolonged mechanical ventilation), and the results have been consistently disappointing or concerning:

Most studies found no improvement in mortality, length of stay, or organ dysfunction. Some trials demonstrated potential harm, including increased cardiac arrhythmias, myocardial oxygen demand and ischemia, and catabolism despite increased metabolic rate. A few studies showed improvements in surrogate endpoints (cardiac index, weaning from vasopressors) without translation to clinical benefit. Trials using T3, T4, or combination therapy all failed to demonstrate clear benefit.

The largest and most rigorous studies, including those in cardiac surgery patients and general ICU populations, have not supported routine thyroid hormone supplementation.

Physiological and Safety Concerns: Administering thyroid hormone to critically ill patients carries specific risks. The cardiovascular system may be particularly vulnerable—increased heart rate and cardiac workload can be poorly tolerated when cardiac reserve is limited, while arrhythmia risk increases substantially, especially in the presence of electrolyte abnormalities or catecholamine support. Increased myocardial oxygen demand may precipitate or worsen ischemia.

Beyond cardiac effects, thyroid hormone administration may increase catabolism and protein breakdown, worsen hyperglycemia through increased gluconeogenesis, complicate temperature regulation, and interfere with the body's adaptive downregulation of metabolism.

Difficulty in Optimal Dosing: Even if treatment were beneficial, determining appropriate dosing in NTIS presents enormous challenges. Normal reference ranges don't apply in critical illness, target levels are unknown, peripheral conversion abnormalities make predicting tissue hormone levels from serum measurements impossible, and the rapid evolution of illness severity means hormone requirements would constantly change.

The disconnect between serum and tissue thyroid hormone concentrations in NTIS means that correcting serum levels may not restore appropriate tissue thyroid hormone action.

Current Guideline Recommendations: Major endocrine and critical care societies uniformly recommend against routine thyroid hormone treatment for NTIS. The American Thyroid Association, Endocrine Society, and Society of Critical Care Medicine all advise that thyroid function testing in critically ill patients should be avoided unless true thyroid disease is specifically suspected, and that abnormal results consistent with NTIS should not prompt treatment.

Differentiating NTIS from True Central Hypothyroidism in the ICU

One of the most challenging diagnostic dilemmas in intensive care medicine is distinguishing NTIS from genuine secondary (central) hypothyroidism—the latter requiring treatment while the former does not. This distinction is particularly difficult because both conditions present with low T4 and inappropriately normal or low TSH.

Clinical Context and History: The patient's history before critical illness provides crucial clues. True central hypothyroidism typically has pre-existing features: known pituitary or hypothalamic disease (tumor, surgery, radiation, infiltrative disease, or traumatic brain injury), chronic symptoms of hypothyroidism preceding acute illness, history suggestive of hypopituitarism (hypotension, hypoglycemia, hypogonadism), or growth failure (in pediatric cases).

Physical examination findings that suggest pre-existing hypothyroidism include stigmata of pituitary disease (visual field defects, pituitary surgery scars), delayed relaxation phase of deep tendon reflexes, and other signs of hypopituitarism (pale, doughy skin; loss of secondary sexual characteristics; postural hypotension).

In contrast, NTIS develops acutely with critical illness onset in patients without prior thyroid-related symptoms.

Laboratory Patterns: While overlap exists, certain laboratory patterns favor one diagnosis over the other:

Features suggesting true central hypothyroidism include markedly low free T4 (typically <0.4-0.5 ng/dL by reliable assay), very low or undetectable TSH (<0.1 mIU/L) that remains persistently suppressed, low T3 proportionate to low T4 (T3:T4 ratio preserved), normal or only mildly elevated rT3, and evidence of other pituitary hormone deficiencies (low cortisol with low ACTH, hypogonadism, low IGF-1).

Features suggesting NTIS include T3 disproportionately low relative to T4, markedly elevated rT3 (typically >0.4 ng/mL), TSH that may be low but often low-normal or even mildly elevated, free T4 that is low but usually not profoundly so, and temporal correlation of thyroid abnormalities with illness severity.

Timing and Evolution: The temporal pattern of thyroid function abnormalities helps differentiate these conditions. NTIS develops acutely with onset of critical illness, worsens with increasing illness severity, and begins to normalize with clinical improvement (often with a "TSH surge"). In contrast, true central hypothyroidism exists before critical illness, remains static rather than tracking with clinical status, and persists unchanged during recovery.

Serial thyroid function testing during the recovery phase is particularly informative—normalization supports NTIS, while persistent abnormalities suggest true thyroid disease.

The Role of TSH: While TSH interpretation is complex in critical illness, certain patterns are more helpful than others. A completely undetectable TSH (<0.01 mIU/L) that persists after recovery suggests either hyperthyroidism or severe central hypothyroidism rather than NTIS. A mildly elevated TSH (2-10 mIU/L) in acute illness actually supports NTIS rather than central hypothyroidism. TSH >20 mIU/L almost always indicates primary hypothyroidism rather than NTIS or central hypothyroidism.

The critical caveat is that isolated TSH measurement during acute illness has limited diagnostic value—serial measurements and clinical context are essential.

Additional Hormone Testing: When central hypothyroidism is suspected, evaluation of other pituitary axes helps establish the diagnosis. Testing should include morning cortisol and ACTH (though interpreting these during critical illness is also complex), LH, FSH, and sex hormones, prolactin (may be elevated with pituitary stalk compression), and IGF-1 and growth hormone (in appropriate contexts).

Multiple pituitary hormone deficiencies strongly suggest true hypopituitarism rather than NTIS.

Practical Approach: A pragmatic diagnostic strategy includes deferring thyroid function testing until truly necessary—avoiding testing in acutely ill patients without specific indication. When testing is performed and reveals abnormalities, clinical assessment should determine whether there is any pre-existing suggestion of pituitary/hypothalamic disease or chronic hypothyroid symptoms. Review medication exposure to drugs affecting thyroid function (amiodarone, lithium, dopamine, glucocorticoids). If history suggests possible central hypothyroidism, test other pituitary axes and use a reliable free T4 assay method (equilibrium dialysis preferred in critical illness).

In ambiguous cases, the safest approach is to defer treatment decisions until after recovery, repeat testing after clinical stabilization (typically 4-6 weeks after hospital discharge), and consult endocrinology for complex cases. In the rare situation where central hypothyroidism must be treated before diagnosis is certain (e.g., severe hypotension despite adequate fluid resuscitation, profound hypothermia, or severe hyponatremia in the context of suspected hypopituitarism), empiric treatment can be initiated with careful monitoring.

Special Situations: Certain clinical scenarios deserve special mention:

Traumatic brain injury patients may develop both NTIS and true central hypothyroidism from pituitary stalk injury—diagnosis requires long-term follow-up. Patients post-pituitary surgery will have true central hypothyroidism superimposed on NTIS—preoperative thyroid function tests are invaluable. Amiodarone exposure causes complex thyroid abnormalities that can mimic NTIS but may require different management. Prolonged critical illness (>2-3 weeks) makes diagnosis increasingly difficult as NTIS patterns evolve and may resemble central hypothyroidism.

The Recovery Phase and the "TSH Surge"

As patients recover from critical illness, thyroid function tests undergo characteristic changes that can paradoxically suggest new thyroid dysfunction if not properly interpreted. Understanding this recovery pattern is essential for avoiding unnecessary testing and treatment.

Timeline of Recovery: Thyroid hormone normalization follows a predictable sequence during recovery. T3 levels begin to rise first, typically within days of clinical improvement, followed by gradual normalization of rT3 levels (which may take weeks to fully resolve). T4 levels normalize later, particularly if they had fallen during severe illness. TSH characteristically shows a transient elevation during recovery—the "TSH surge."

The complete normalization process typically takes 4-8 weeks after resolution of critical illness, though it may be prolonged after particularly severe or protracted illness.

The TSH Surge Phenomenon: The TSH surge represents one of the most important yet underrecognized aspects of NTIS recovery. As peripheral thyroid hormone levels begin to normalize and the suppressive effects of critical illness resolve, the hypothalamic-pituitary axis "awakens" and TSH secretion rebounds. This often results in transient TSH elevation, sometimes reaching 10-20 mIU/L or occasionally higher, while T4 and T3 are still normalizing.

This elevation typically peaks 2-4 weeks after the acute illness and gradually resolves over subsequent weeks. The TSH surge can easily be misinterpreted as primary hypothyroidism, particularly if it is the first thyroid function test obtained during recovery or if the patient's critical illness history is not fully appreciated.

Distinguishing TSH Surge from Primary Hypothyroidism: Several features help differentiate the recovery-phase TSH surge from true primary hypothyroidism:

TSH surge characteristics include timing corresponding to recovery phase (not acute illness), TSH elevation that is usually mild to moderate (typically 10-20 mIU/L, rarely >30), free T4 that is normal or low-normal (not profoundly low), T3 that is normalizing or normal (not low), presence of elevated rT3 (still clearing from illness), resolution with serial testing over 4-8 weeks, and clinical improvement rather than hypothyroid symptoms.

Primary hypothyroidism characteristics include TSH typically >20 mIU/L (often >50-100 in overt disease), markedly low free T4, low T3 proportionate to T4, normal rT3, persistent or worsening thyroid function abnormalities on serial testing, and clinical hypothyroid symptoms.

Management During Recovery: The appropriate management of thyroid function abnormalities during recovery from critical illness requires restraint and patience. The key principles include avoiding thyroid function testing during the recovery phase unless specific concern for thyroid disease exists. If testing is performed and shows isolated TSH elevation with normal or low-normal T4, repeat testing in 4-6 weeks rather than initiating treatment. Educating patients that thyroid test abnormalities during recovery are expected and do not indicate thyroid disease.

Consider thyroid antibody testing (TPO, thyroglobulin antibodies) if there is concern for primary hypothyroidism—their presence would suggest true thyroid disease. Only initiate levothyroxine treatment if TSH remains elevated (>10 mIU/L) with low T4 on repeat testing 6-8 weeks after recovery, or if there is strong clinical suspicion of pre-existing hypothyroidism.

Long-Term Considerations: While most patients' thyroid function completely normalizes after NTIS, certain populations warrant ongoing vigilance. Patients with severe or prolonged critical illness may have delayed recovery taking 3-6 months. Those with traumatic brain injury, subarachnoid hemorrhage, or pituitary surgery risk developing permanent central hypothyroidism that may not be apparent until months after injury. Patients who had borderline thyroid function before illness may develop overt hypothyroidism unmasked by the critical illness stress.

Follow-up thyroid function testing should be performed 3-6 months after critical illness in patients with severe traumatic brain injury or pituitary region injury, those who had thyroid function abnormalities persisting at hospital discharge, and those developing symptoms suggestive of hypothyroidism during recovery.

Clinical Vignette: A typical scenario illustrates these principles: A 62-year-old man is recovering from severe sepsis requiring 10 days in the ICU. During acute illness, his TSH was 0.5 mIU/L and free T4 was 0.7 ng/dL (low). Three weeks after ICU discharge, his primary care physician checks thyroid function: TSH is now 15 mIU/L, free T4 is 1.0 ng/dL (low-normal).

The physician, concerned about the elevated TSH, considers starting levothyroxine. However, recognizing this pattern as a TSH surge during recovery from NTIS, the appropriate management is to reassure the patient, explain that this represents normal recovery from severe illness, and repeat testing in 4-6 weeks. Subsequent testing shows TSH 3.5 mIU/L and free T4 1.2 ng/dL—complete normalization without treatment.

---

Summary

Non-thyroidal illness syndrome represents a coordinated adaptive response to severe illness involving altered peripheral thyroid hormone metabolism, modified central regulation, and changed cellular thyroid hormone action. The characteristic pattern—low T3, high rT3, and eventually low T4 with inappropriately normal or low TSH—reflects the complex interplay of deiodinase dysregulation, inflammatory cytokine effects, and hypothalamic-pituitary axis changes.

Rather than representing a hormone deficiency requiring replacement, NTIS appears to be a protective mechanism that conserves energy and resources during critical illness. Multiple clinical trials have failed to demonstrate benefit from thyroid hormone supplementation, and current guidelines recommend against treatment except in very rare circumstances.

The major clinical challenges lie in differentiating NTIS from true central hypothyroidism requiring treatment, and in recognizing the normal recovery pattern with its characteristic TSH surge that can mimic primary hypothyroidism. A thorough understanding of NTIS prevents both unnecessary testing during acute illness and inappropriate treatment during recovery, while ensuring that patients with genuine thyroid disease are identified and appropriately managed. 

References

1. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015;3(10):816-825.

2. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005;90(8):4559-4565.

3. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid. 2014;24(10):1456-1465.

4. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev. 2011;32(5):670-693.

5. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev. 1982;3(2):164-217.

6. Chopra IJ, Huang TS, Beredo A, Solomon DH, Teco GN, Mead JF. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab. 1985;60(4):666-672.

7. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003;88(7):3202-3211.

8. Mebis L, Langouche L, Visser TJ, Van den Berghe G. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab. 2007;92(8):3330-3333.

9. Angelousi AG, Karageorgopoulos DE, Kapaskelis AM, Falagas ME. Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. Eur J Endocrinol. 2011;164(2):147-155.

10. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1-8.

11. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333(23):1522-1527.

12. Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med. 1982;10(12):870-875.

13. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84(1):151-164.

14. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57(1):293-298.

15. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.

16. Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A. Thyroid function during critical illness. Hormones (Athens). 2011;10(2):117-124.

17. Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 1998;83(6):1827-1834.

18. Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab. 1986;62(4):717-722.

19. Zargar AH, Ganie MA, Masoodi SR, Laway BA, Bashir MI, Wani AI. Prevalence and pattern of sick euthyroid syndrome in acute and chronic non-thyroidal illness--its relationship with severity and outcome of the disorder. J Assoc Physicians India. 2004;52:27-31.

20. Langouche L, Vander Perre S, Wouters PJ, D'Hoore A, Hansen TK, Van den Berghe G. Effect of intensive insulin therapy on insulin sensitivity in the critically ill. J Clin Endocrinol Metab. 2007;92(10):3890-3897.